Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) has established, if current pricing holds, a new 52-week high. The previous high was $4.70 but at 3:33 M CST, BLCI shares are trading above $4.80. Volumes are exceptionally heavy. The normal average daily volume is listed at 176,500 but almost 2 million shares have traded so far. On December 13, 2016 BCLI shares closed at $2.16. Should BCLI shares close at $4.80 today, that would represent a gain of over 220% in less than 15 weeks.
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) is a clinical-stage biotechnology company that develops stem cell therapies for neurodegenerative diseases including Lou Gehrig’s disease (ALS), Multiple Sclerosis, Parkinson’s, and Huntington’s disease. Their proprietary platform technology is NurOwn and utilizes proprietary culture conditions to induce mesenchymal stem cells to secrete neurotrophic factors known to promote the survival of neurons. Brainstorm’s research has shown that these types of cells might be an effective tool for treating neurodegenerative diseases. NurOwn has been administered to approximately 75 patients with ALS in clinical trials conducted in the United States and Israel. In a randomized, double-blind, placebo-controlled clinical trial conducted in the U. S., a clinically meaningful benefit was demonstrated by higher response to NurOwn compared with placebo.
Today’s price activity takes BCLI shares up almost 13% and to a Relative Strength value of over 70 which begins to enter what many traders consider “overbought” territory. Volumes have been large. Today over 2 million shares of BCLI have traded hands even though their average daily volume is just 176,500. Momentum players filter databases for stocks with these types of growth and volume characteristics so it would not be unusual to see volumes at historical highs for Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI).
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) has no reported sales. The number of outstanding shares has increased YoY since 2012 when there were 9.17 million shares. By 2016 that number was at 18.66 million. Zack’s is the sole analyst covering Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) and they rate BCLI shares as a “Strong Buy”.
|Last Price a/o 3:30 PM EST||$ 4.80|
|Market Cap (mlns)||$ 81.94|
|Shares Outstanding (mlns)||19.28|
|Share Float (mlns)||16.2|
|Short Interest Ratio||5.03|
I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.
About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.